Genetic predisposition accounts for 5–10% of all breast cancers (BC) diagnosed. NCCN guidelines help providers identify appropriate candidates for counseling and testing. Concerns about underutilization of genetic testing have spurred interest in broader peri-diagnostic testing. We evaluated surgeon adherence to NCCN guidelines and studied patterns of testing in newly diagnosed BC patients.
A total of 397 patients were identified with newly diagnosed BC treated at our institution between 2016 and 2017 with no prior genetic testing. Eligibility for genetic testing based on NCCN criteria, referral, and patient compliance were recorded.
In total, 212 of 397 (53%) met NCCN testing criteria. Fifty-nine of 212 (28%) patients went untested despite meeting one or more criteria. Fourteen of 59 (24%) of these were referred but did not comply. Most common criteria for meeting eligibility for testing both in the overall cohort and among missed patients were family history-based. Age > 45 years old and non-Ashkenazi Jewish descent were predictive of missed referral (p < 0.01). We identified pathogenic mutations in 16 of 153 (10%) patients who did undergo testing (11 (7%) BRCA1 or 2 and 5 (3%) with other predisposition gene mutations) or 16 of 397 (4%) among the overall group.
Our data highlight the underutilization of genetic testing. Even in the setting of a full-service breast center with readily available genetic counseling, there is a substantial miss rate for identifying eligible patients, related to assessment of family history, patient age, and ethnicity, as well as patient compliance. Broader peri-diagnostic testing should be considered, and higher compliance rates with patients referred should be sought.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
American Cancer Society: Breast Cancer Facts and Figures 2017-2018. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/breast-cancer-facts-and-figures-2017-2018.pdf.
DeSantis C, Ma J, Bryan L, et al. Breast cancer statistics, 2013. CA Cancer J Clin. 2014;64(1):52–62. https://doi.org/10.3322/caac.21203.
Lokich E, Stuckey A, Raker C, Wilbur JS, Laprise J, Gass J. Preoperative genetic testing affects surgical decision making in breast cancer patients. Gynecol Oncol. 2014;134:326–33.
Schwarts GF, Hughes KS, Lynch HT et al. Proceeding of the international consensus conference on breast cancer risk, genetics and risk management, April 2007. Cancer. 2008:113:2627–37.
Pharoah PD, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BA. Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet. 2002;31:33–6.
Walsh T, Lee MK, Casadei S, et al. Detection of inherited pathogenic variants for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc Natl Acad Sci USA. 2010:107:12629–33.
Walsh T, King MC. Ten genes for inherited breast cancer. Cancer Cell. 2007:11:103–5.
Van der Groep P, van der Wall E, van Diest PJ. Pathology of hereditary breast cancer. Cell Oncol (Dordr). 2011:34:71–88.
NCCN. NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High Risk Assessment: Breast, Ovarian and Pancreatic. Version 1.2020—Dec 04, 2019. https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf.
Guo F, Hirth J, Lin YL, et al. Use of BRCA mutation test in the U.S., 2004–2014. Am J Prev Med. 2017:52(6):702–9.
Guo F, Scholl M, Fuchs EL, Berenson AB, Kuo YF. BRCA testing in unaffected young women in the United States, 2006–2017. Cancer. 2020:15;126(2):337–43.
Yang S, Axilbund JE, O’Leary E, et al. Underdiagnosis of hereditary breast and ovarian cancer in Medicare patients: genetic testing criteria miss the mark. Ann Surg Oncol. 2018; 25:2925–31.
Matro JM, Ruth KJ, Wong YN, et al. Cost sharing and hereditary cancer risk: predictors of willingness-to-pay for genetic testing. J Genet Couns. 2014;23:1002–11.
Kurian A, Kent G, Hamilton A, et al. Genetic testing and counseling among patients with newly diagnosed breast cancer. JAMA. 2017; 317(5):531–4.
Childers C, Childers KK, Maggard-Gibbons M, Macinko J. National estimates of genetic testing in women with a history of breast or ovarian cancer. J Clin Oncol. 2017; 35(34):3800–6.
Hughes K. Genetic testing: what problem are we trying to solve? J Clin Oncol. 2017; 35:3789–92.
Brown KL, Hutchinson R, Zinberg RE, McGovern MM. Referral and experience with genetic testing among women with early onset breast cancer. Genet Test. 2005;9:301–5.
Stuckey A, Febbraro T, Laprise J, et al. Adherence patters to National Comprehensive Cancer Network guidelines for referral of women with breast cancer to genetic professionals. Am J Clin Oncol. 2016;39:363–7.
Assessing the Status of BRCA testing and the challenges faced by Cancer Care Teams in the Community: summary of survey findings. April 2018. https://www.accc-cancer.org/docs/projects/brca/brca-initiative_survey-summary_final-v2.pdf?sfvrsn=80fe0ffb_2.
Narod S, Akbari MR. Population-based genetic testing for BRCA1 and BRCA2. J Clin Oncol. 2018; 36(5):517.
Kishan A, Gomez C, Dawson N, et al. Increasing appropriate BRCA1/2 mutation testing: the role of family history documentation and genetic counseling in a multidisciplinary clinic. Ann Surg Oncol. 2016; 23:S634–41.
The American Society of Breast Surgeons Consensus Guideline on Genetic Testing for Hereditary Breast Cancer. 2019. https://www.breastsurgeons.org/docs/statements/Consensus-Guideline-on-Genetic-Testing-for-Hereditary-Breast-Cancer.pdf.
Beitsch P, Whitworth P, Hughes K et al. Underdiagnosis of hereditary breast cancer: are genetic testing guidelines a tool or an obstacle? J Clin Oncol. 2017;37:453–62.
Raphael J, Verma S, Hewitt P, Eisen A. The impact of Angelina Jolie (AJ)’s story on genetic referral and testing at an academic cancer centre in Canada. J Genet Couns. 2016;25(6):1309–16.
Gabai-Kapara E, Lahad A, Kaufman B, et al. Population-based screening for breast and ovarian cancer risk due to BRCA 1 and BRCA 2. Proc Natl Acad Sci USA. 2014;111(39):14205–10.
Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997;336:1401–8.
Roa BB, Boyd AA, Vocik K, Richards CS. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet. 1996;14:185–7.
Lieberman S, Tomer A, Ben-Chetrir A, et al. Population screening for BRCA1/BRCA2 founder mutations in Ashkenazi Jews: proactive recruitment compared with self-referral. Genet Med. 2017;19(7):754-62.
Liberman S, Lahad A, Tomer A, Cohen C, Levy-Lahad E. Population screening for BRCA1/2 mutations: lessons from qualitative analysis of the screening experience. Genet Med. 2017; 19(6):628–34.
Helwick C. Dr. Marie King proposes population screening in all young women for BRCA mutations. The ASCO post, 2015. http://www.ascopost.com/issues/february-10-2015/dr-mary-claire-king-proposes-population-screening-in-all-young-women-for-brca-mutations/.
The authors declare no conflicts of interest.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Alberty-Oller, J.J., Weltz, S., Santos, A. et al. Adherence to NCCN Guidelines for Genetic Testing in Breast Cancer Patients: Who Are We Missing?. Ann Surg Oncol (2020). https://doi.org/10.1245/s10434-020-09123-z